The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

The capital injection will facilitate the clinical progression of Arbor's ABO-101, the lead therapeutic candidate targeting ...

Indeed, present-day genetic testing has an accuracy rate of ... researchers often turned to people's ABO phenotypes when such issues arose; however, ABO blood group information could only be ...

PH1 is a rare genetic disorder in which enzyme deficiencies in the liver lead to the overproduction and buildup of oxalate, resulting in kidney stones eventually leading to end stage kidney disease ...

The genetic risk factors for most patients with pancreatic cancer are unknown, although Wolpin and colleagues have discovered an association between ABO blood group and the risk of pancreatic cancer.

ABO-101 is designed to knock down HAO1 gene expression ... is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions – from the ultra-rare to ...

The proceeds will support clinical development of the company's lead therapeutic candidate, ABO-101, in primary hyperoxaluria ... of potentially curative genetic medicines for patients,” said ...